Skip to main content
Erschienen in: Tumor Biology 8/2015

01.08.2015 | Research Article

Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression

verfasst von: Fan Yang, Jian Wang, Hua-yan Ren, Juan Jin, Ai-lian Wang, Li-li Sun, Ke-xin Diao, En-hua Wang, Xiao-yi Mi

Erschienen in: Tumor Biology | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

In this study, we examined protein arginine methyltransferase 5 (PRMT5) and tumor necrosis factor receptor-associated 4 (TRAF4) expression in breast cancer to find the interaction mechanism between the two. We examined TRAF4 and PRMT5 expression by immunohistochemistry and found that their expression is positively correlated in breast cancer. Besides, PRMT5 expression was significantly associated with histological type and tumor size (p < 0.05). PRMT5 nuclear expression was significantly associated with HER2 expression (p < 0.05). PRMT5 and TRAF4 were both overexpressed in breast cancer tissues and cells, and we found that PRMT5 binds to the zinc finger structures in TRAF4 by coimmunoprecipitation and Western blotting. We also tested the potential regulatory effect between TRAF4 and PRMT5. TRAF4 upregulated PRMT5 expression, which occurred predominantly in the nucleus, on which TRAF4 promotion of cell proliferation in breast cancer is mainly dependent. PRMT5 may play an important role in activation of the NF-κB signaling pathway.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal. 2001;13:389–400.CrossRefPubMed Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal. 2001;13:389–400.CrossRefPubMed
2.
Zurück zum Zitat Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 2002;115(Pt4):679–88.PubMed Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 2002;115(Pt4):679–88.PubMed
3.
Zurück zum Zitat Mathew SJ, Rembold M, Leptin M. Role for Traf4 in polarizing adherens junctions as a prerequisite for efficient cell shape changes. Mol Cell Biol. 2011;31:4978–93.CrossRefPubMedPubMedCentral Mathew SJ, Rembold M, Leptin M. Role for Traf4 in polarizing adherens junctions as a prerequisite for efficient cell shape changes. Mol Cell Biol. 2011;31:4978–93.CrossRefPubMedPubMedCentral
4.
5.
Zurück zum Zitat Kalkan T, Iwasaki Y, Park CY, Thomsen GH. Tumor necrosis factor-receptor-associated factor-4 is a positive regulator of transforming growth factor-beta signaling that affects neural crest formation. Mol Biol Cell. 2009;20:3436–50.CrossRefPubMedPubMedCentral Kalkan T, Iwasaki Y, Park CY, Thomsen GH. Tumor necrosis factor-receptor-associated factor-4 is a positive regulator of transforming growth factor-beta signaling that affects neural crest formation. Mol Biol Cell. 2009;20:3436–50.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ahmed F, Shiraishi T, Vessella RL, Kulkarni P. Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a. Oncol Rep. 2013;30(6):2963–8.PubMed Ahmed F, Shiraishi T, Vessella RL, Kulkarni P. Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a. Oncol Rep. 2013;30(6):2963–8.PubMed
7.
8.
Zurück zum Zitat Regnier CH, Tomasetto C, Moog-Lutz C, et al. Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem. 1995;270(43):25715–21.CrossRefPubMed Regnier CH, Tomasetto C, Moog-Lutz C, et al. Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem. 1995;270(43):25715–21.CrossRefPubMed
9.
Zurück zum Zitat Zapata JM, Matsuzawa S, Godzick A, Leo E, Wasserman SA, Reed JC. The drosophila tumor necrosis factor receptor-associated factor-1 (DTRAF1) interacts with pelle and regulates NFkappaB activity. J Biol Chem. 2000;275(16):12102–7.CrossRefPubMed Zapata JM, Matsuzawa S, Godzick A, Leo E, Wasserman SA, Reed JC. The drosophila tumor necrosis factor receptor-associated factor-1 (DTRAF1) interacts with pelle and regulates NFkappaB activity. J Biol Chem. 2000;275(16):12102–7.CrossRefPubMed
10.
Zurück zum Zitat Kuranaga E, Kanuka H, Igaki T, et al. Reaper-mediated inhibition of DIAPl-induced DTRAF1 degradation results in activation of JNK in Drosophila. Nat Cell Biol. 2002;4(9):705–10.CrossRefPubMed Kuranaga E, Kanuka H, Igaki T, et al. Reaper-mediated inhibition of DIAPl-induced DTRAF1 degradation results in activation of JNK in Drosophila. Nat Cell Biol. 2002;4(9):705–10.CrossRefPubMed
11.
Zurück zum Zitat Li JM, Fan LM, Christie MR, Shah AM. Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells: role of p47phox phosphorylation and binding to TRAF4. Mol Cell Biol. 2005;25(6):2320–30.CrossRefPubMedPubMedCentral Li JM, Fan LM, Christie MR, Shah AM. Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells: role of p47phox phosphorylation and binding to TRAF4. Mol Cell Biol. 2005;25(6):2320–30.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ren J, Wang Y, Liang Y, Zhang Y, Bao S, Xu Z. Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis. J Biol Chem. 2010;285(17):12695–705.CrossRefPubMedPubMedCentral Ren J, Wang Y, Liang Y, Zhang Y, Bao S, Xu Z. Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis. J Biol Chem. 2010;285(17):12695–705.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Zhou Z, Sun X, Zou Z, et al. PRMT5 regulates Golgi apparatus structure through methylation of the golgin GM130. Cell Res. 2010;20(9):1023–33.CrossRefPubMed Zhou Z, Sun X, Zou Z, et al. PRMT5 regulates Golgi apparatus structure through methylation of the golgin GM130. Cell Res. 2010;20(9):1023–33.CrossRefPubMed
15.
Zurück zum Zitat Dacwag CS, Bedford MT, Sif S, Imbalzano AN. Distinct protein arginine methyltransferases promote ATP-dependent chromatin remodeling function at different stages of skeletal muscle differentiation. Mol Cell Biol. 2009;29(7):1909–21.CrossRefPubMedPubMedCentral Dacwag CS, Bedford MT, Sif S, Imbalzano AN. Distinct protein arginine methyltransferases promote ATP-dependent chromatin remodeling function at different stages of skeletal muscle differentiation. Mol Cell Biol. 2009;29(7):1909–21.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Mallappa C, Hu YJ, Shamulailatpam P, Tae S, Sif S, Imbalzano AN. The expression of myogenic microRNAs indirectly requires protein arginine methyltransferase (Prmt)5 but directly requires Prmt4. Nucleic Acids Res. 2011;39(4):1243–55.CrossRefPubMed Mallappa C, Hu YJ, Shamulailatpam P, Tae S, Sif S, Imbalzano AN. The expression of myogenic microRNAs indirectly requires protein arginine methyltransferase (Prmt)5 but directly requires Prmt4. Nucleic Acids Res. 2011;39(4):1243–55.CrossRefPubMed
17.
Zurück zum Zitat Eckert D, Biermann K, Nettersheim D, et al. Expression of BLIMP1/PRMT5 and concurrent histone H2A/H4 arginine 3 dimethylation in fetal germ cells, CIS/ IGCNU and germ cell tumors. BMC Dev Biol. 2008;8:106.CrossRefPubMedPubMedCentral Eckert D, Biermann K, Nettersheim D, et al. Expression of BLIMP1/PRMT5 and concurrent histone H2A/H4 arginine 3 dimethylation in fetal germ cells, CIS/ IGCNU and germ cell tumors. BMC Dev Biol. 2008;8:106.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Tanaka H, Hoshikawa Y, Oh-hara T, et al. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res. 2009;7(4):557–69.CrossRefPubMed Tanaka H, Hoshikawa Y, Oh-hara T, et al. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res. 2009;7(4):557–69.CrossRefPubMed
19.
Zurück zum Zitat Gu Z, Li Y, Lee P, Liu T, Wan C, Wang Z. Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. Plos One. 2012;7(8):e44033.CrossRefPubMedPubMedCentral Gu Z, Li Y, Lee P, Liu T, Wan C, Wang Z. Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. Plos One. 2012;7(8):e44033.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Nicholas C, Yang J, Peters SB, et al. PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27 (Kip1.). Plos One. 2013;8(9):e74710.CrossRefPubMedPubMedCentral Nicholas C, Yang J, Peters SB, et al. PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27 (Kip1.). Plos One. 2013;8(9):e74710.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Bao X, Zhao S, Liu T, Liu Y, Liu Y, Yang X. Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem. 2013;61(3):206–17.CrossRefPubMedPubMedCentral Bao X, Zhao S, Liu T, Liu Y, Liu Y, Yang X. Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem. 2013;61(3):206–17.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Rozan LM, El-Deiry WS. Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target. Cancer Biol Ther. 2006;5(9):1228–35.CrossRefPubMed Rozan LM, El-Deiry WS. Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target. Cancer Biol Ther. 2006;5(9):1228–35.CrossRefPubMed
23.
Zurück zum Zitat Zhang X, Wen Z, Sun L, et al. TRAF2 regulates the cytoplasmic/nuclear distribution of TRAF4 and its biological function in breast cancer cells. Biochem Biophys Res Commun. 2013;436(2):344–8.CrossRefPubMed Zhang X, Wen Z, Sun L, et al. TRAF2 regulates the cytoplasmic/nuclear distribution of TRAF4 and its biological function in breast cancer cells. Biochem Biophys Res Commun. 2013;436(2):344–8.CrossRefPubMed
24.
Zurück zum Zitat Harris DP, Bandyopadhyay S, Maxwell TJ, Willard B, DiCorleto PE. Tumor necrosis factor (TNF)-α induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-κB p65 methylation. J Biol Chem. 2014;289(22):15328–39.CrossRefPubMedPubMedCentral Harris DP, Bandyopadhyay S, Maxwell TJ, Willard B, DiCorleto PE. Tumor necrosis factor (TNF)-α induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-κB p65 methylation. J Biol Chem. 2014;289(22):15328–39.CrossRefPubMedPubMedCentral
25.
26.
Zurück zum Zitat Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS. Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 2011;71(16):5579–87.CrossRefPubMedPubMedCentral Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS. Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 2011;71(16):5579–87.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11(18):6598–607.CrossRefPubMed Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11(18):6598–607.CrossRefPubMed
28.
Zurück zum Zitat Salmon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.CrossRef Salmon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.CrossRef
29.
Zurück zum Zitat Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res. 2002;62(3):652–5.PubMed Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res. 2002;62(3):652–5.PubMed
30.
Zurück zum Zitat Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappa B (NF-kappa B) signaling in breast cancer. J Cell Physiol. 2006;209(3):645–52.CrossRefPubMed Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappa B (NF-kappa B) signaling in breast cancer. J Cell Physiol. 2006;209(3):645–52.CrossRefPubMed
Metadaten
Titel
Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression
verfasst von
Fan Yang
Jian Wang
Hua-yan Ren
Juan Jin
Ai-lian Wang
Li-li Sun
Ke-xin Diao
En-hua Wang
Xiao-yi Mi
Publikationsdatum
01.08.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 8/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3262-0

Weitere Artikel der Ausgabe 8/2015

Tumor Biology 8/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.